<DOC>
	<DOCNO>NCT02221310</DOCNO>
	<brief_summary>Targeted immune therapy gemtuzumab ozogamicin ( Mylotarg ) combination chemotherapy follow allogeneic stem cell transplantation give patient high risk acute myelogenous leukemia ( AML ) myelodysplastic syndrome ( MDS ) .</brief_summary>
	<brief_title>Immunochemotherapy AlloSCT Patients With High Risk CD33+ AML/MDS</brief_title>
	<detailed_description>Gemtuzumab ozogamicin combination busulfan cyclophosphamide ( immunochemotherapy ) conditioning follow allogeneic stem cell transplantation + anti-thymocyte globulin ( unrelated donor ) patient high risk CD33+AML MDS meeting eligibility criterion .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<criteria>Disease Status : History AML Induction/Reinduction Failure AML 1st Complete Remission ( CR ) poor cytogenetics AML 2nd CR minimal residual disease ( MRD ) AML 3rd CR AML refractory relapse ≤25 % bone marrow leukemia blast MDS &gt; 6 % bone marrow blast diagnosis Secondary MDS ≤5 % bone marrow myeloblasts diagnosis Disease Immunophenotype : • Disease must express minimum &gt; /= 10 % CD33+ patient AML Organ Function : • Adequate renal function , adequate liver function , adequate cardiac function , adequate pulmonary function Age : ≤30 year age Donor : match family donor , unrelated cord blood donor , unrelated adult donor Patients active central nervous system ( CNS ) AML/MDS disease time condition therapy Female patient pregnant Karnofsky &lt; 50 % Lansky &lt; 50 % 10 year less Age &gt; 31 year Has receive gemtuzumab previous 30 day recover prior gemtuzumab therapy .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>target therapy</keyword>
	<keyword>leukemia</keyword>
	<keyword>MDS</keyword>
	<keyword>immune therapy</keyword>
</DOC>